Synthesis of Chiral 1,2-Amino Alcohol-Containing Compounds Utilizing Ruthenium-Catalyzed Asymmetric Transfer Hydrogenation of Unprotected α-Ketoamines
作者:Hari P. R. Mangunuru、Leila Terrab、Venumadhav Janganati、Nageswara Rao Kalikinidi、Srinivasarao Tenneti、Vasudevan Natarajan、Arun D. R. Shada、Santhosh Reddy Naini、Praveen Gajula、Daniel Lee、Lalith P. Samankumara、Manasa Mamunooru、Aravindan Jayaraman、Rajkumar Lalji Sahani、Jinya Yin、Chathuranga C. Hewa-Rahinduwage、Aravind Gangu、Anji Chen、Zhirui Wang、Bimbisar Desai、Tai Y. Yue、Chaitanya S. Wannere、Joseph D. Armstrong、Kai O. Donsbach、Gopal Sirasani、B. Frank Gupton、Bo Qu、Chris H. Senanayake
DOI:10.1021/acs.joc.4c00045
日期:——
steps. We identified a facile synthetic protocol via a highly enantioselective one-step process for epinephrine and a two-step process for norepinephrine starting from unprotected α-ketoamines 1b and 1a, respectively. This newly developed enantioselective ruthenium-catalyzed asymmetric transfer hydrogenation was extended to the synthesis of many 1,2-amino alcohol-containing drug molecules such as phenylephrine
在此,我们公开了一种简单的合成策略,以利用高效钌催化的未保护 α-酮胺的不对称转移氢化来获得一类重要的药物分子,这些分子包含手性 1,2-氨基官能团。最近,由于需求增加,COVID-19 大流行导致许多重要药物短缺危机,尤其是去甲肾上腺素和肾上腺素,用于治疗过敏反应和低血压。遗憾的是,由于现有的冗长合成方案需要额外的保护和脱保护步骤,因此现有技术无法满足全球要求。我们通过肾上腺素的高对映选择性一步法和去甲肾上腺素的两步法分别从未受保护的 α-酮胺 1b 和 1a 开始,确定了一种简单的合成方案。这种新开发的对映选择性钌催化的不对称转移氢化被扩展到许多含 1,2-氨基醇的药物分子的合成,如去氧肾上腺素、地诺巴胺、去甲布芽碱和左旋异丙肾上腺素,对映选择性为 >99% ee,分离产率高。